Wegovy Pill Just Changed: Why Lilly Stock Could Still Win
A new oral Wegovy launch is reshaping GLP-1 dynamics. Even with Novo Nordisk gaining ground, Eli Lilly stock could st...
Discover ways to make money from hobbies and turn your passions into profitable ventures. Start monetizing your interests now!
13,170 articlesA new oral Wegovy launch is reshaping GLP-1 dynamics. Even with Novo Nordisk gaining ground, Eli Lilly stock could st...
XRp has logged a year of regulatory and liquidity wins, but the price keeps drifting lower. Analysts say macro headwi...
AbbVie just agreed to buy Apogee Therapeutics for $10.9 billion in cash. This move could reshape the company’s cash f...
When a CFO discloses a sizable stake sale during a volatile period, investors scramble for context. This article brea...
Tech stocks rallied on renewed concerns about memory supply and rising data-center energy costs. Analysts warn that t...
Oklo has zigzagged from a peak near $193 to much lower levels, raising questions about its momentum and prospects. Th...
CFOs are increasingly moving into the CEO chair, but AI-driven disruption is testing how long they can stay. New data...
Prices are cooling and mortgage rates linger above historical lows. This piece unpacks whether we’re at a turning poi...
A bold take on Tesla's future: could the Optimus robot redefine the company and its stock by 2026? This article lays ...
Want to understand how Extra Space Storage (EXR) earns and how to read its earnings calls like a pro? This deep dive ...
If you’ve got $1,000 to invest, you don’t need to chase the hottest hype. Here are three durable stocks that recently...
AAPD’s 3.43% yield looks appealing, but the bear-on-Apple fund relies on collateral interest instead of dividends. A ...